Trial reportAmerican journal of respiratory and critical care medicine2016
Desipramine Increases Genioglossus Activity and Reduces Upper Airway Collapsibility during Non-REM Sleep in Healthy Subjects.
Trial report in American journal of respiratory and critical care medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02428478 (The Effect of Desipramine on Genioglossus Muscle Activity During Sleep in Healthy Control Subjects), which is not on this map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Desipramine on Genioglossus Muscle Activity During Sleep in Healthy Control Subjects
Who cites it
52 citing papers in PubMed, 81 citations in OpenAlex.
- Acetazolamide to prevent ventilatory drive withdrawal in REM sleep apnoea: a randomised controlled trial.Thorax · 2026Trial
- Atomoxetine plus oxybutynin for symptomatic snoring and airflow limitation in individuals without moderate-to-severe obstructive sleep apnea.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2025Trial
- A single dose of noradrenergic/serotonergic reuptake inhibitors combined with an antimuscarinic does not improve obstructive sleep apnoea severity.Physiological reports · 2022Trial
- Different antimuscarinics when combined with atomoxetine have differential effects on obstructive sleep apnea severity.Journal of applied physiology (Bethesda, Md. : 1985) · 2021Trial
- Trial
- Trial
- The Combination of Atomoxetine and Oxybutynin Greatly Reduces Obstructive Sleep Apnea Severity. A Randomized, Placebo-controlled, Double-Blind Crossover Trial.American journal of respiratory and critical care medicine · 2019Trial
- Trial
- Phenotyping-based treatment improves obstructive sleep apnea symptoms and severity: a pilot study.Sleep & breathing = Schlaf & Atmung · 2017Trial
- Effect of 4-Aminopyridine on Genioglossus Muscle Activity during Sleep in Healthy Adults.Annals of the American Thoracic Society · 2017Trial
- Desipramine improves upper airway collapsibility and reduces OSA severity in patients with minimal muscle compensation.The European respiratory journal · 2016Trial
- Preoperative video laryngoscopic examination for difficult intubation in obese patients.Die Anaesthesiologie · 2026Article
- Leptin alleviates obesity hypoventilationbioRxiv : the preprint server for biology · 2026Article
- Review
- Obstructive Sleep Apnea: An Evolving Therapeutic Landscape with an Emerging Role for Incretin-Based Therapies.Advances in therapy · 2025Review
- Research Priorities for Translating Endophenotyping of Adult Obstructive Sleep Apnea to the Clinic: An Official American Thoracic Society Research Statement.American journal of respiratory and critical care medicine · 2025Article
- Drive versus Pressure Contributions to Genioglossus Activity in Obstructive Sleep Apnea.Annals of the American Thoracic Society · 2023Article
- Sleep and Breathing Conference highlights 2023: a summary by ERS Assembly 4.Breathe (Sheffield, England) · 2023Article
- Medical Treatment of Obstructive Sleep Apnea in Children.Journal of clinical medicine · 2023Review
- Pathophysiological mechanisms and therapeutic approaches in obstructive sleep apnea syndrome.Signal transduction and targeted therapy · 2023Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
7 authors at 2 institutions in 3 countries.
Funding
Abstract
rationaleObstructive sleep apnea is a state-dependent disease. One of the key factors that triggers upper airway collapse is decreased pharyngeal dilator muscle activity during sleep. To date, there have not been effective methods to reverse pharyngeal hypotonia pharmacologically in sleeping humans.
objectivesWe tested the hypothesis that administration of desipramine 200 mg prevents the state-related reduction in genioglossus activity that occurs during sleep and thereby decreases pharyngeal collapsibility.
methodsWe conducted a placebo-controlled, double-blind, crossover trial with 10 healthy participants. Participants received active treatment or placebo in randomized order 2 hours before sleep in the physiology laboratory. MEASUREMENTS AND MAIN
resultsGenioglossus activity during wakefulness and sleep, genioglossus muscle responsiveness to negative epiglottic pressure, and upper airway collapsibility during passive and active conditions were compared between on- and off-drug states. Desipramine abolished the normal reduction of genioglossus activity from wakefulness to non-REM sleep that occurred on the placebo night. Specifically, tonic (median, 96% [86-120] vs. 75% [50-92] wakefulness; P = 0.01) but not phasic genioglossus activity was higher with desipramine compared with placebo. Upper airway collapsibility was also reduced with desipramine compared with placebo (-10.0 cm H
conclusionsDesipramine reduces the state-related drop in tonic genioglossus muscle activity that occurs from wakefulness to non-REM sleep and reduces airway collapsibility. These data provide a rationale for a new pharmacologic therapy for obstructive sleep apnea. Clinical trial registered with www.clinicaltrials.gov (NCT02428478).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.